The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the investigational new drug application for a ...

Drugs and other treatments can be quite effective at killing cancer cells, yet many fall short as they struggle to penetrate ...

Cornell researchers have confirmed that a previously identified biomarker for detecting the presence of malignant testicular ...

The AACR poster presentation will provide an update on the data in AML patients most recently presented at the American ...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

TK-6302, a supercharged PRAME TCR-T cell therapy containing a high affinity TCR, an activating CD8 coreceptor (costimCD8 CoR) ...

BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...

Dr. Hadiyah-Nicole Green has developed a novel cancer-killing technology, Laser-Activated NanoTherapy (LANT), that is of high ...